Valuation: Gennex Laboratories Limited

Market Cap 1.99B 21.07M 18.81M 17.26M 15.7M 29.44M 30.03M 206M 83.11M 1.05B 79.07M 77.39M 3.33B P/E 2025
15.4x
P/E 2026 8.26x
Enterprise Value 2.41B 25.5M 22.77M 20.89M 19M 35.63M 36.34M 250M 101M 1.27B 95.7M 93.66M 4.02B EV / Sales 2025
1.79x
EV / Sales 2026 1.25x
Free-Float
66.61%
Yield 2025 *
-
Yield 2026 -
10-01 Gennex Laboratories Limited Announces Board Changes CI
08-14 Gennex Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
05-30 Gennex Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
02-14 Gennex Laboratories Limited Resignation of Shilpa Bung, Non-Executive Independent Women Director, Effective February 14, 2026 CI
02-14 Gennex Laboratories Limited Appoints Khushbu Kachhawa as Additional Director (Non-Executive Independent Women Director) CI
02-14 Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
11-14 Gennex Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
14/08/25 Gennex Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
30/05/25 Gennex Laboratories Limited Announces Resignation of Dr. Sch Dharma Rao as Non-Executive Non-Independent Director, Effective May 30, 2025 CI
30/05/25 Gennex Laboratories Limited Appoints Sandeep Kumar Daga as Non-Executive Non-Independent Director CI
30/05/25 Gennex Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 CI
14/02/25 Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
14/02/25 Gennex Laboratories Limited Announces Resignation of Mohammed Khaleequr Rahman as Non-Executive Non-Independent Director CI
1 day+6.58%
1 week-1.46%
Current month+9.10%
1 month-11.62%
3 months-3.31%
6 months-13.71%
Current year-38.81%
1 week 7.7
Extreme 7.7
9.21
1 month 7.7
Extreme 7.7
10.25
Current year 7.05
Extreme 7.05
14.77
1 year 7.05
Extreme 7.05
16.3
3 years 7.05
Extreme 7.05
29
5 years 4.81
Extreme 4.81
29
10 years 1.32
Extreme 1.32
29
Manager TitleAgeSince
Chief Executive Officer 40 18/05/2012
Director of Finance/CFO - 12/11/2024
Compliance Officer 62 20/04/2023
Director TitleAgeSince
Chairman 40 -
Director/Board Member - 21/12/2020
Director/Board Member 62 01/10/2024
Change 5-day change 1-year change 3-year change Capi.($)
+6.58%-1.46%-43.40%-22.29% 21.07M
-0.46%+10.31%+63.52%+143.15% 1,257B
-0.97%+1.60%+43.25%+80.09% 651B
-2.05%+0.73%+32.47%+101.62% 510B
-0.19%-0.83%+52.49%+66.79% 388B
-0.78%+5.51%+72.55%+44.25% 366B
+0.75%+2.78%+33.03%+58.82% 303B
-0.12%+7.92%+11.92%+34.73% 288B
-0.12%+4.68%+55.97%+74.59% 252B
-0.21%+7.34%+42.19%+109.69% 211B
Average +0.46%+3.69%+36.40%+69.14% 422.67B
Weighted average by Cap. -0.38%+5.30%+49.19%+93.65%

Financials

2025 2026
Net sales 1.38B 14.57M 13.01M 11.93M 10.86M 20.35M 20.76M 143M 57.46M 728M 54.67M 53.5M 2.3B 1.73B 18.25M 16.29M 14.95M 13.6M 25.5M 26M 179M 71.97M 912M 68.48M 67.02M 2.88B
Net income 181M 1.91M 1.71M 1.57M 1.43M 2.67M 2.73M 18.73M 7.55M 95.65M 7.18M 7.03M 302M 210M 2.22M 1.98M 1.82M 1.65M 3.1M 3.16M 21.68M 8.74M 111M 8.32M 8.14M 350M
Net Debt -275M -2.9M -2.59M -2.38M -2.16M -4.06M -4.14M -28.4M -11.45M -145M -10.89M -10.66M -458M 420M 4.43M 3.96M 3.63M 3.3M 6.19M 6.31M 43.36M 17.48M 221M 16.63M 16.28M 699M
Projected Income Statement - Annual - Gennex Laboratories Limited
Logo Gennex Laboratories Limited
Gennex Laboratories Limited is an India-based active pharmaceutical ingredient manufacturing company. The Company is engaged in the business of manufacturing of bulk drugs and intermediaries. It offers products in various therapeutic categories, including expectorant (mucolyte), relaxant (skeletal muscle relaxant), antihistamines, urinary tract analgesic, antifungals called triazoles, tricyclic antidepressant, acting muscle relaxants, muscle relaxant, selective serotonin reuptake inhibitors (SSRIS), and xanthine oxidase inhibitors. Its products include Guaifenesin, Methocarbamol, Fexofenadine Hcl, Phenazopyridine Hcl, Fluconazole, Melitracen Hcl, Mephenesin, Chlorphenesin, Sertraline Hcl and Allopurinol. The Company has manufacturing facilities in India which cater to both domestic and international markets. Its international markets include Bangladesh, Bolivia, China, Colombia, Costa Rica, Cuba, Germany, Indonesia, Iran, Iraq, Israel, Jordan, Kenya, South Korea, Malaysia and Mexico.
Employees
125
Date Price Change Volume
03/11/26 ₹8.750 +6.58% 321,525
02/11/26 ₹8.210 +2.37% 1,053,207
30/10/26 ₹8.020 -10.49% 1,321,688
29/10/26 ₹8.960 -1.54% 188,622
28/10/26 ₹9.100 +2.48% 286,354
  1. Stock Market
  2. Stocks
  3. GENNEX6 Stock